Saletu B, Grünberger J, Anderer P, Linzmayer L, König P
Department of Psychiatry, School of Medicine, University of Vienna, Austria.
Arzneimittelforschung. 1995 Mar;45(3):217-29.
In a double-blind, placebo-controlled study, the effects of caroverine (CAS 23465-76-1, Spasmium)--a quinoxaline derived from isoquinoline, the basic structure of papaverine, originally developed as a spasmolytic drug which may, however, exert central effects due to an unspecific calcium channel blocking action and glutamate antagonism--were investigated utilizing EEG-mapping, psychometric and psychophysiological measures. Fifteen healthy volunteers (8 males and 7 females), aged 20-35 years, received randomized and at weekly intervals 40 and 80 mg caroverine intravenously, 40 and 80 mg caroverine orally, as well as placebo. EEG recordings, psychometric and psychophysiological tests, as well as evaluation of pulse, blood pressure and side-effects were carried out at 0, 1, 2, 4, 6 and 8 h. Multivariate analysis of EEG mapping data demonstrated that caroverine exerted a significant action on human brain function, as compared with placebo, at all given dosages, as early as in the 1st and as late as in the 8th hour after both intravenous and oral administration during resting (R-EEG) and vigilance-controlled recording (V-EEG). Subsequent univariate analyses revealed, however, differential effects of caroverine--dependent on recording conditions and doses. In the resting condition, an increase of absolute and relative delta and theta power, a decrease of alpha and beta power and a slowing of the centroid of the delta and theta activity occurred, reflecting sedative action. The latter was slightly time- and dose-dependent (more sedation in earlier hours after higher doses). However, in the vigilance-controlled EEG, a dose-dependent decrease of delta and theta power, an increase of alpha power and an acceleration of the centroid of the delta and theta suggested vigilance-promoting effects, which were more pronounced in the later than earlier hours. Psychometric investigations confirmed these differential central effects. In regard to the noopsyche, an improvement was noted 6 h after the lowest oral dose. In the thymopsyche, a deterioration occurred after all doses except the highest oral dose, suggesting sedation. The latter was also seen after all active compounds as a trend in psychophysiological variables. The drug was well tolerated.
在一项双盲、安慰剂对照研究中,使用脑电图地形图、心理测量和心理生理测量方法,对卡维林(CAS 23465 - 76 - 1,Spasmium)——一种从异喹啉衍生而来的喹喔啉,罂粟碱的基本结构,最初开发用作解痉药物,但由于非特异性钙通道阻断作用和谷氨酸拮抗作用可能产生中枢效应——的效果进行了研究。15名年龄在20至35岁之间的健康志愿者(8名男性和7名女性),随机且每周一次静脉注射40毫克和80毫克卡维林、口服40毫克和80毫克卡维林以及服用安慰剂。在0、1、2、4、6和8小时进行脑电图记录、心理测量和心理生理测试,以及脉搏、血压和副作用评估。脑电图地形图数据的多变量分析表明,与安慰剂相比,卡维林在所有给定剂量下,早在静脉注射和口服后的第1小时以及晚至第8小时,在静息(R - EEG)和警觉控制记录(V - EEG)期间,对人脑功能均有显著作用。然而,随后的单变量分析显示,卡维林的作用存在差异——取决于记录条件和剂量。在静息状态下,绝对和相对δ波和θ波功率增加,α波和β波功率降低,δ波和θ波活动的质心减慢,反映出镇静作用。后者略有时间和剂量依赖性(高剂量后早期更具镇静作用)。然而,在警觉控制脑电图中,δ波和θ波功率呈剂量依赖性降低,α波功率增加,δ波和θ波的质心加速,表明具有促进警觉的作用,在后期比早期更明显。心理测量研究证实了这些不同的中枢效应。关于智力,在最低口服剂量后6小时观察到有所改善。在情感方面,除最高口服剂量外,所有剂量后均出现恶化,表明有镇静作用。在所有活性化合物后,心理生理变量也呈现出这种趋势。该药物耐受性良好。